Our findings support a reduction in NAbs over time, with ACE2-RBD inhibition of median 46.8% demonstrated in participants with infection following the second vaccine dose a median 85 days prior to sampling, in contrast to 16.2% in individuals with natural infection and vaccination a median 415 days prior to sampling. The gene discussed is ACE2; the disease is infection.